International Journal of Drug Delivery Technology
Volume 14, Issue 2

Lornoxicam Solid Lipid Nanoparticle-Enriched Transdermal Gel:Development and Characterization

Vaibhav Dagaji Aher1, Rajesh V2, Renukaradhya Chitti2, Boi Basanta Kumar Reddy3*

1Department of Pharmaceutical Medicine, Maharashtra University of Health Sciences, Nashik, Maharashtra, India

2Department of Pharmacy Practice, Sri Adichunchanagiri College of Pharmacy, B.G., Nagamangala, Karnataka, India

3Department of Pharmaceutics, Danteswari College of Pharmacy, Jagdalpur, Chhattisgarh, India 

Received: 09th January, 2024; Revised: 10th March, 2024; Accepted: 08th April, 2024; Available Online: 25th June, 2024 

ABSTRACT

To develop antiinflammation and analgesic effects, scientists introduced lornoxicam (LRX) nanoemulsion, nanostructure lipid carriers, and solid lipid nanoparticles. After six months of testing at different temperatures, SLN, NLC, and NE were determined to be stable. The most prominent mechanism that was identified in case I was the diffusional release of drugs from nanoparticles and nanoemulsion, which is consistent with Fickian drug diffusion. After NE, NLC, and SLN, a gel formulation achieved the greatest rate of drug penetration via rat skin. When contrasted with the gel, nanoformulations considerably enhanced the drug’s penetration into the skin of rats. Therefore, SLN, NLC, and NE of LRX could be recommended for the relief of skin disorders characterized by inflammation and pain.

Keywords: Solid lipid nanoparticles, Nanostructured lipid carriers, Lornoxicam, Nanoformulations.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.2.29

How to cite this article: Aher VD, Rajesh V, Chitti R, Reddy BBK. Lornoxicam Solid Lipid Nanoparticle-Enriched Transdermal Gel: Development and Characterization. International Journal of Drug Delivery Technology. 2024;14(2):792-796.

REFERENCES

  1. Wissing SA, Müller The influence of solid lipid nanoparticles on skin hydration and viscoelasticity – in vivo study. Eur J Pharm Biopharm. 2003; 56:67–72.
  2. Jenning Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm 2003; 49:211–18.
  3. Schäfer-Korting M. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Delivery Rev 2007; 59:427–43.
  4. Mandawgade SD, Patravale VB. Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int J Pharm. 2008; 363:132–38.
  5. Mei Z. Solid lipid nanoparticle and microemulsion for topical delivery of Eur J Pharm Biopharm. 2003; 56:189– 96.
  6. Chen Podophyllotoxin- loaded solid lipid nanoparticles for epidermal targeting. J Control Release 2006; 110:296–306.
  7. Lv Q. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int J Pharm 2009; 372:191–98.
  8. Balfour Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 1996; 51(4):639-57.
  9. Radhofer-Welte S, Rabasseda X. Lornoxicam, a new potent NSAID with an improved tolerability profile. Drugs Today (Barc). 2000; 36:55-76.
  10. Meastrelli F. Effect of preparation technique on the properties of liposomes encapsulating ketoprofen-cyclodextrin complexes aimed for transdermal delivery. Int J Pharm 2006; 312:53-60.
  11. Battaglia Solid lipid nanoparticles formed by solvent-in-water emulsion-diffusion technique: Development and influence on insulin stability. J Microencapsul 2007; 24:672–84.
  12. Thombre NA, Niphade PS, Ahire ED, Kshirsagar Formulation development and evaluation of microemulsion based lornoxicam gel. Biosci. Biotechnol. Res. Asia 2022 Mar 31;19(1):69-80.
  13. Shah M, Pathak K. Development and statistical optimization of solid lipid nanoparticles of simvastatin by using 23 full-factorial designs. AAPS Pharm SciTech 2010; 11:489–96.
  14. Das MK, Ahmed AB. Formulation and ex-vivo evaluation of rofecoxib gel for topical application. Acta Pol. Pharm. 2007; 64:461-67.
  15. Zhu WW. Formulation design of microemulsion for dermal delivery of penciclovir. Int J Pharm 2008; 360:184–90.
  16. Wissing Investigations on the occlusive properties of solid lipid nanoparticles (SLN), J Cosmet Sci 2001; 52:313–23.
  17. Van-Abbe NJ. Exaggerated exposure in topical irritancy and sensitization testing. J Soc Cosmet Chem 1975; 26:173.
  18. Ammar HO. Proniosomes as a carrier system for transdermal delivery of tenoxicam. Int J Pharm 2011; 405:142–52.
  19. Chin CT, Chun Anti-inflammatory effects of Taiwan folk medicine ‘Teng-Khia-U’ on carrageenan-and adjuvant-induced paw edema in rats. J Ethnopharm 1999; 64:85–89.
  20. Ghamdi The anti-inflammatory, analgesic and antipyretic activity of Nigella sativa. J Ethnopharm 2001; 76:45–48.
  21. Perez HD, Weissmann Lysozymes as mediators of inflammation. In: Keller W, et al, eds. Textbook of rheumatology. Philadelphia7: W.B Saunders, 1981: 179– 194.
  22. Majno G, Joris L. Cells, Tissues and Disease: Principles of General Pathology. Blackwell Science: Cambridge, 1996.
  23. Perez Anti-inf lammatory activity of Ambrosia artemisiaefolia and Rheospathaceae. Phytomedicine 1996; 3:163–67.
  24. Seyle H. Further studies concerning the participation of adrenal cortex in the pathogenesis of arthritis. Bri Med Journal 1949; 2:1129–135.
  25. Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm 2008; 346:124–32.